Clinical Monograph • Medically Reviewed
Crestor
Rosuvastatin Calcium • Hydrophilic Statin (Lipid Lowering Agent)
Clinical Overview: Highly potent hydrophilic HMG-CoA reductase inhibitor possessing extended hepatoselectivity and negligible cytochrome P450 3A4 interaction.
Therapeutic Indications & Pharmacodynamics
Rosuvastatin exhibits high uptake into human hepatocytes via organic anion transporting polypeptides. Proven in the JUPITER trial to reduce primary cardiovascular endpoints even in normolipidemic patients with elevated high-sensitivity C-reactive protein (hsCRP).
Clinical Indications
Severe hypercholesterolemia, slowing progression of coronary atherosclerosis, primary prevention of cardiovascular disease.
Contraindications & Precautions
Active hepatic impairment, severe renal impairment (CrCl < 30 mL/min), co-administration with cyclosporine.
Prescribing Profile
Available Strengths:
5mg, 10mg, 20mg, 40mg
5mg, 10mg, 20mg, 40mg
Elimination Half-Life:
Approximately 19 hours
Approximately 19 hours
Reviewing Physician:
Dr. Caroline Hernandez, MD
Dr. Caroline Hernandez, MD
Institutional Dosing Monograph